BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Olsutamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Olsutamig\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05125016-11300@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20300328
DTEND;VALUE=DATE:20300329
SUMMARY:Olsutamig: Phase 1/2 readout est. (NCT05125016)
DESCRIPTION:Olsutamig\, phase 1/2\, Prostate Cancer.\nStudy: A Trial to Fin
 d Out if REGN4336 is Safe and How Well it Works Alone and in Combination W
 ith REGN5678 for Adult Participants With Advanced Prostate Cancer\nEstimat
 ed primary completion: 28 March 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/olsutamig#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05125016
URL:https://assetmemo.bio/drug/olsutamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594106-11300@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20301027
DTEND;VALUE=DATE:20301028
SUMMARY:Olsutamig: Phase 1/2 readout est. (NCT07594106)
DESCRIPTION:Olsutamig\, phase 1/2\, Prostate Cancer.\nStudy: REGN15505 (PSM
 Ax4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in
  Adult Patients With Metastatic Castration-Resistant Prostate Cancer and C
 lear Cell Renal Cell Carcinoma\nEstimated primary completion: 27 October 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/olsutamig#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07594106
URL:https://assetmemo.bio/drug/olsutamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
